Delcath Systems Email Formats
Pharmaceutical Manufacturing • 
Manhattan, New York, United States • 101-200 Employees
Delcath Systems Email Formats
Delcath Systems uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@delcath.com), used 50.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@delcath.com | 50.5% |
{first name}{last name} | johndoe@delcath.com | 43% |
{last name}{last name} | doedoe@delcath.com | 6.5% |
Key Contacts at Delcath Systems
Company overview
| Headquarters | 1633 Broadway, 22nd Floor, Suite C, New York, NY 10019, US |
| Phone number | +19179026455 |
| Website | |
| NAICS | 3254 |
| SIC | 283 |
| Keywords | Research & Development, Oncology, Uveal Melanoma, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Cancers, Ocular Melanoma, Hepatic Dominant Uveal Melanoma, Liver Directed Therapy, Metastatic Uveal Melanoma |
| Founded | 1987 |
| Employees | 101-200 |
| Socials |
About Delcath Systems
Delcath Systems, Inc. (NASDAQ- DCTH) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. Our proprietary product---Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. Delcath is in late-stage clinical development in the United States with initial commercial activities in Europe, where the Melphalan/HDS is marketed as a CE Marked device under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). Our commercial strategy for CHEMOSAT is to steadily grow clinical adoption in major European markets and utilize physician experience to support appeals for reimbursement. Since launch over 250 CHEMOSAT treatments have been performed at over 20 leading European cancer centers. In 2016, we launched our FOCUS Pivotal Study in Hepatic Dominant Ocular Melanoma, and are investigating orphan indications in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. We believe Melphalan/HDS is uniquely positioned to treat the entire liver as a stand-alone or complementary therapy.
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
Delcath Systems has 69 employees across 14 departments.
Departments
Number of employees
Funding Data
Explore Delcath Systems's funding history, including investment rounds, total capital raised, and key backers.
Delcath Systems Tech Stack
Discover the technologies and tools that power Delcath Systems's digital infrastructure, from frameworks to analytics platforms.
Video players
Security
Security
JavaScript libraries
Analytics
UI frameworks
JavaScript libraries
CDN
SEO
JavaScript libraries
Miscellaneous
Germany
Poland
United Kingdom
Belgium
AustraliaFrequently asked questions
4.8
40,000 users
